Immuneel Therapeutics Raises Rs 100 Crore to Expand CAR-T Cancer Therapy Production
Immuneel Therapeutics, a Bengaluru-based cancer therapy startup co-founded by Biocon founder Kiran Mazumdar-Shaw, has raised over Rs 100 crore from investors including Singularity AMC and Rainmatter. The company develops CAR-T therapy, a personalized cancer treatment that modifies patients' immune cells to fight blood cancers. The funding will support scaling manufacturing, reducing treatment costs to about one-tenth of Western prices, and expanding into Southeast Asia, Asia Pacific, and the Middle East.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (75/100). Lens Score 39/100 — moderate-to-low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- economictimes— balanced framing, positive sentiment
- economictimes— balanced framing, positive sentiment
AI Analysis
The articles focus on a business and healthcare development without political framing. They highlight investment and innovation in cancer treatment, presenting perspectives from company leadership and investors. The coverage is neutral, emphasizing technological advancement and market expansion without political commentary or partisan viewpoints.
The tone across the articles is generally positive, emphasizing progress in making advanced cancer therapy more accessible and affordable. The coverage highlights the potential benefits of the funding round and the company's goals, with no critical or negative sentiment evident.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.